MedTrace Logo

A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics

NCT04603989 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-02-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety , tolerability and pharmacokinetics after multiple ascending of HNC042 given to healthy Chinese volunteers, compared to placebo.

Conditions

Interventions

DRUG

HNC042 for Injection

HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg

DRUG

Placebo Comparator

Placebo , Intravenous route , multiple ascending doses

Sponsors & Collaborators

  • Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Guangzhou Henovcom Bioscience Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Lu Xiang, MD · Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2020-11-13
Completion
2020-11-13
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04603989 on ClinicalTrials.gov